Novo Nordisk Named Most Sustainable Pharma Company

Novo Nordisk Named Most Sustainable Pharma Company

tweet me:
Novo Nordisk receives top position in the pharma industry group on the 2016 Global 100 Most Sustainable Corporations

Multimedia from this Release


Today, the 2016 Global 100 Most Sustainable Companies Index was released at the World Economic Forum in Davos. Novo Nordisk ranked 19 on the Global 100 Index and regained the number one position in the pharmaceutical industry.

Thursday, January 21, 2016 - 9:30am

CONTENT: Press Release

Davos, Switzerland, January 21, 2016 /3BL Media/ - Today, Novo Nordisk received the top position in the pharmaceuticals industry group on the 2016 Global 100 Most Sustainable Corporations in the World (Global 100) Index. Overall, the company ranked 19, a decrease of six places from 2015. The Index highlights the global companies that are most proactive in managing their environmental and social performance as well as corporate governance issues.

Novo Nordisk’s ranking is reflects the company’s strong performance on maintaining a balanced CEO to average worker pay ratio, improved carbon productivity by decreasing carbon emissions while growing revenue and mechanisms in place to tie executive management compensation to corporate sustainability performance.

“Our focus is on meeting the needs of people living with chronic conditions. To do this we must always consider how our decision may benefit their health and well-being as well as our impacts on people, communities and the environment,” says Susanne Stormer, Vice President of Corporate Sustainability, Novo Nordisk. “Sustainability for Novo Nordisk is about staying in business for the next generations and our Triple Bottom Line approach is how we think long-term to be a successful business success and deliver more value to our customers.”

Companies named to the Global 100 index are the top overall sustainability performers in their respective industrial sectors, selected from a starting universe of 4,609 listed companies with a market capitalization greater than $2 billion (USD).

The Global 100 is determined using twelve quantitative sustainability indicators, including the amount of revenue companies generate per unit of energy consumed, the ratio of CEO to average worker pay and lost-time injury rate.

For full rankings please visit

Read more about Novo Nordisk’s Triple Bottom Line approach to business


About the Global 100 Index
The Global 100 process begins each year on October 1, when the starting universe for the index is established. Companies in the starting universe are put through four screens, and the companies that emerge constitute the Global 100 Shortlist. Companies in the Shortlist are then scored on the priority KPIs for their particular GICS Industry. The top overall performers from each GICS Sector are named to the final Global 100, subject to the number of slots reserved for each GICS Sector.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit, Facebook, Twitter, LinkedIn, YouTube